AJR Am J Roentgenol
- BURGIO MD
Prognostic Value of LI-RADS CT/MRI Radiation Treatment Response Assessment
Version 2024 in Hepatocellular Carcinoma Treated with Y-90 Radioembolization.
AJR Am J Roentgenol. 2025 May 14. doi: 10.2214/AJR.25.33219.
- KELLER EJ
If You Can Superselect a Hepatic Artery, You Can Learn Prompt Engineering.
AJR Am J Roentgenol. 2025 May 14. doi: 10.2214/AJR.25.33212.
- HORII SC
Determination of the Hepatic Attenuation Coefficient: Importance of a Scanning
Protocol That Accounts for the Ultrasound Machine and Depth of the Hepatic ROI.
AJR Am J Roentgenol. 2025 May 14. doi: 10.2214/AJR.25.33148.
- GABRIEL H
The Urgent Need for Standardizing Ultrasound Quantification of Hepatic Steatosis.
AJR Am J Roentgenol. 2025 May 14. doi: 10.2214/AJR.25.33161.
Am J Gastroenterol
- HWANG SY, Rezaee-Zavareh MS, Attia AM, Kaymen EA, et al
Immune-related Adverse Events are Associated with Improved Outcomes after Immune
Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma: A Systematic Review
and Meta-analysis.
Am J Gastroenterol. 2025 May 16. doi: 10.14309/ajg.0000000000003546.
Am J Pathol
- XUE Y, Tian T, Ottallah M, Mannan M, et al
Alcohol-Associated Hepatocarcinogenesis: Wnt/beta-Catenin in Action.
Am J Pathol. 2025 May 9:S0002-9440(25)00156-7. doi: 10.1016/j.ajpath.2025.
Biochem Biophys Res Commun
- FAN M, Wu J, Wu Y, Zhang Y, et al
SETDB1 decline promotes the resistance to sorafenib via DRP1
phosphorylation-mediated mitochondrial dysfunction in HepG2 cells.
Biochem Biophys Res Commun. 2025;768:151934.
BMC Cancer
- HOSSEINKHAN N, Najafi L, Jahangiri S, Emami Z, et al
Statin use and risk of HCC in patients with MASLD and T2DM: an umbrella review
and meta-analysis.
BMC Cancer. 2025;25:875.
- SHU Z, Ye T, Wu W, Su M, et al
Preoperative plasma cell-free DNA chromosomal instability predicts microvascular
invasion in hepatocellular carcinoma: a prospective study.
BMC Cancer. 2025;25:867.
- YANG H, Shen S, Yang Y, Zhou H, et al
Platelet-albumin-bilirubin versus albumin-bilirubin as a predictor of long-term
survival for hepatitis B-Induced hepatocellular carcinoma after hepatic
resection.
BMC Cancer. 2025;25:855.
- REIERSON MM, Acharjee A
Unsupervised machine learning-based stratification and immune deconvolution of
liver hepatocellular carcinoma.
BMC Cancer. 2025;25:853.
- PELOSO A, Pietrasz D, Daillier E, Cylly L, et al
Resection and partial liver transplantation from deceased donors with delayed
total hepatectomy (RAPID procedure) for hepatocellular carcinoma: a national,
multicenter, non-randomized, prospective trial.
BMC Cancer. 2025;25:848.
BMC Gastroenterol
- XU S, Ji Q, Xu J
Evaluating the diagnostic significance of the R2* value on 3.0T MRI for assessing
the severity of warm hepatic ischemia-reperfusion injury.
BMC Gastroenterol. 2025;25:361.
- YE D, Wang J, Shi J, Ma Y, et al
Prevalence of MAFLD in the U.S. based on NHANES 2009-2018: differences in
demographic characteristics, physical indices and lifestyle conditions.
BMC Gastroenterol. 2025;25:329.
- LE XY, Feng JB, Yu XL, Li SL, et al
A network meta-analysis of different interventional treatment strategies for
unresectable hepatocellular carcinoma.
BMC Gastroenterol. 2025;25:360.
- QIAO G, Feng L, Wang M, Wang C, et al
Eradication of Helicobacter pylori that contributes to hepatogenic ulcer is
beneficial to the healing of hepatogenic ulcer.
BMC Gastroenterol. 2025;25:359.
- XU Z, Xu B
Nonlinear association between AST/ALT ratio and 28-day all-cause mortality
following ICU admission in critically ill cirrhotic patients: a retrospective
cohort study.
BMC Gastroenterol. 2025;25:367.
- LIU G, Mao Q, Tian X, Zhang C, et al
Association of biological aging and the prevalence of nonalcoholic fatty liver
disease: a population-based study.
BMC Gastroenterol. 2025;25:368.
- MATSUMOTO K, Doi S, Adachi T, Watanabe A, et al
Surface area outcomes in EUS-guided liver biopsy: a comparative study of Franseen
and Fork-tip needles.
BMC Gastroenterol. 2025;25:370.
- WU J, Yu W, Huang L, Hou S, et al
The HbA1c/HDL-C ratio as a screening indicator of NAFLD in U.S. adults: a
cross-sectional NHANES analysis (2017-2020).
BMC Gastroenterol. 2025;25:369.
- PENG HY, Lu CL, Zhao M, Huang XQ, et al
Clinical characteristics of MASLD/MetALD/MAFLD/NAFLD and the relative risk
analysis on metabolic disorders.
BMC Gastroenterol. 2025;25:372.
- WANG X, Chen H, Wang L, Sun W, et al
Machine learning for predicting all-cause mortality of metabolic
dysfunction-associated fatty liver disease: a longitudinal study based on NHANES.
BMC Gastroenterol. 2025;25:376.
- WANG C
Role of liver transient elastography in detecting cirrhosis with esophageal and
gastric varices and evaluating variceal severity.
BMC Gastroenterol. 2025;25:379.
Endoscopy
- INOUE T, Kitano R, Kitada T, Futagami S, et al
Endoscopic ultrasound-guided hepaticogastrostomy with antegrade stenting using a
catheter-like delivery system: a novel technique completely omitting the fistula
dilation step.
Endoscopy. 2025;57.
Eur Radiol
- VERDAN S, Torri GB, Marcos VN, Moreira MHS, et al
Ultrasound-derived fat fraction for diagnosing hepatic steatosis: a systematic
review and meta-analysis.
Eur Radiol. 2025 May 9. doi: 10.1007/s00330-025-11652.
- ELBANNA KY, Khalili K, AlMoharb M, Goel A, et al
Qualitative and quantitative assessment of gadoxetic acid MRI in distinguishing
atypical focal nodular hyperplasia from hepatocellular adenoma subtypes.
Eur Radiol. 2025 May 14. doi: 10.1007/s00330-025-11679.
- TIE J, Yuan X, Liu Z, Gou X, et al
Transjugular mesenteric-caval shunt for portal vein cavernous transformation with
recurrent variceal bleeding: preliminary results.
Eur Radiol. 2025;35:3256-3261.
- KOBAYASHI T, Kozaka K, Matsubara T, Yokka A, et al
Super delayed phase imaging in gadoxetic acid-enhanced MRI: investigating factors
contributing to improved liver contrast.
Eur Radiol. 2025;35:3195-3205.
- LI J, Li Y, Chen YY, Wang XY, et al
Predicting post-hepatectomy liver failure with T1 mapping-based whole-liver
histogram analysis on gadoxetic acid-enhanced MRI: comparison with the
indocyanine green clearance test and albumin-bilirubin scoring system.
Eur Radiol. 2025;35:3587-3598.
- JING HH, Hao D, Liu XJ, Cui MJ, et al
Development and validation of a radiopathomics model for predicting liver
metastases of colorectal cancer.
Eur Radiol. 2025;35:3409-3417.
- IMAJO K, Saigusa Y, Kobayashi T, Nagai K, et al
Head-to-head comparison among FAST, MAST, and multiparametric MRI-based new score
in diagnosing at-risk MASH.
Eur Radiol. 2025;35:3599-3609.
- EL HOMSI M, Bou Ayache J, Fernandes MC, Horvat N, et al
Comparison of abbreviated and complete MRI protocols for treatment response
assessment of colorectal liver metastases.
Eur Radiol. 2025;35:3450-3459.
- JENSEN CT, Wong VK, Likhari GS, Daoud TE, et al
Dual-energy CT for differentiation of hypodense liver lesions in pancreatic
adenocarcinoma.
Eur Radiol. 2025;35:3538-3546.
- JIANG H, Li B, Zheng T, Qin Y, et al
MRI-based prediction of microvascular invasion/high tumor grade and adjuvant
therapy benefit for solitary HCC = 5 cm: a multicenter cohort study.
Eur Radiol. 2025;35:3223-3237.
Gastroenterology
- SHUNG DL, Iacucci M
Artificial Intelligence in Gastroenterology and Hepatology: Potential and Perils.
Gastroenterology. 2025 May 13:S0016-5085(25)00710.
Hepatology
- JIN Y, Wang M, Xu A, Xu B, et al
Letter to the Editor: Association between mean arterial pressure and terlipressin
in the reversal of hepatorenal syndrome-acute kidney injury.
Hepatology. 2025 May 15. doi: 10.1097/HEP.0000000000001404.
- WANG Y, Yang L, Li M, Hao J, et al
Proenkephalin produced by neonatal T-bet+ Treg cells promotes periportal
hepatocyte maturation.
Hepatology. 2025 May 12. doi: 10.1097/HEP.0000000000001389.
- WANG C, Dong D, Zhao N, Zhao S, et al
Hepatocyte-specific C-C motif chemokine ligand 9 signaling promotes liver
fibrosis progression in mice.
Hepatology. 2025 May 9. doi: 10.1097/HEP.0000000000001393.
- YANG DL, Li YF, Li YJ, Qiu GG, et al
Reply: Survival benefit of transarterial chemoembolization combined with tyrosine
kinase and immune checkpoint inhibitors as conversion therapy for unresectable
hepatocellular carcinoma needs more details.
Hepatology. 2025 May 9. doi: 10.1097/HEP.0000000000001395.
- YU TC, Zhao L, Sze KM, Tian L, et al
GPD1L supports glycerol-3-phosphate and triacylglycerol synthesis and promotes
tumor progression in hepatocellular carcinoma.
Hepatology. 2025 May 9. doi: 10.1097/HEP.0000000000001394.
J Comput Assist Tomogr
- ZHU X, Zhu J, Sun C, Zhu F, et al
Prediction of Local Tumor Progression After Thermal Ablation of Colorectal Cancer
Liver Metastases Based on Magnetic Resonance Imaging Delta-Radiomics.
J Comput Assist Tomogr. 2025;49:377-384.
J Gastroenterol Hepatol
- LIOU WL, Tan SY, Yamada H, Krishnamoorthy T, et al
Performance of the GALAD Model in an Asian Cohort Undergoing Hepatocellular
Carcinoma Surveillance: A Prospective Cohort Study.
J Gastroenterol Hepatol. 2025 May 10. doi: 10.1111/jgh.16997.
- QIN J, Zhu W, Zhou W
Navigating the Paradox of IL-22: Friend or Foe in Hepatic Health?
J Gastroenterol Hepatol. 2025 May 13. doi: 10.1111/jgh.16991.
- CHANG YW, Kuo CN, Chang CL, Hsu JC, et al
Sequential Treatment of Metastatic Colorectal Cancer in Taiwan: Real-World
Evidence From Regorafenib and Trifluridine/Tipiracil Use.
J Gastroenterol Hepatol. 2025;40:1135-1142.
- FUKAMIZO K, Hagiwara Y, Kimura T, Matsuyama Y, et al
Individualized Effects of Weight Gain in Adulthood on the Development of MASLD in
Japanese Non-Obese Individuals.
J Gastroenterol Hepatol. 2025;40:1255-1262.
- DONG L, Zhang H, Kang Y, Wang F, et al
NLRP3 and Gut-Liver Axis: New Possibility for the Treatment of Alcohol-Associated
Liver Disease.
J Gastroenterol Hepatol. 2025;40:1070-1078.
J Hepatol
-
EASL Clinical Practice Guidelines on extrahepatic abdominal surgery in patients
with cirrhosis and advanced chronic liver disease.
J Hepatol. 2025 May 8:S0168-8278(25)00235-1. doi: 10.1016/j.jhep.2025.
- CHRISTAKI M, Biros D, Tsiakas I, Milionis H, et al
Carvedilol is superior to propranolol in preventing first and further
decompensation, and mortality in patients with cirrhosis.
J Hepatol. 2025 May 7:S0168-8278(25)00291-0. doi: 10.1016/j.jhep.2025.
Lancet
- VITHAYATHIL M, Sharma R
Nivolumab plus ipilimumab in hepatocellular carcinoma.
Lancet. 2025 May 7:S0140-6736(25)00417-9. doi: 10.1016/S0140-6736(25)00417.
- YAU T, Galle PR, Decaens T, Sangro B, et al
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment
for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label,
randomised, phase 3 trial.
Lancet. 2025 May 7:S0140-6736(25)00403-9. doi: 10.1016/S0140-6736(25)00403.
N Engl J Med
- NOUREDDIN M, Rinella ME, Chalasani NP, Neff GW, et al
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH.
N Engl J Med. 2025 May 9. doi: 10.1056/NEJMoa2502242.
Oncogene
- DENG L, Tang J, Yang H, Cheng C, et al
Retraction Note: MTA1 modulated by miR-30e contributes to
epithelial-to-mesenchymal transition in hepatocellular carcinoma through an
ErbB2-dependent pathway.
Oncogene. 2025 May 12. doi: 10.1038/s41388-025-03433.
PLoS One
- TAKADA H, Osawa L, Komiyama Y, Muraoka M, et al
Serum interferon-gamma-induced protein 10 levels can help predict sarcopenia
development in patients with primary hepatocellular carcinoma: A retrospective
cohort study.
PLoS One. 2025;20:e0309852.
- NGAMSANGIAM W, Techa-Ay S, Sa-Ngiamwibool P, Watcharadetwittaya S, et al
Distinct chromosome abnormality patterns for differential diagnosis of
hepatocellular carcinoma and cholangiocarcinoma.
PLoS One. 2025;20:e0322408.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016